DE602005015605D1 - Hcv impfstoff für chronische hcv patienten - Google Patents

Hcv impfstoff für chronische hcv patienten

Info

Publication number
DE602005015605D1
DE602005015605D1 DE602005015605T DE602005015605T DE602005015605D1 DE 602005015605 D1 DE602005015605 D1 DE 602005015605D1 DE 602005015605 T DE602005015605 T DE 602005015605T DE 602005015605 T DE602005015605 T DE 602005015605T DE 602005015605 D1 DE602005015605 D1 DE 602005015605D1
Authority
DE
Germany
Prior art keywords
hcv
vaccinate
patients
chronic
chronic hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005015605T
Other languages
English (en)
Inventor
Juergen Frisch
Erich Tauber
Vera Buerger
Christoph Klade
Michael Buschle
Katherine Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of DE602005015605D1 publication Critical patent/DE602005015605D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE602005015605T 2004-10-29 2005-09-23 Hcv impfstoff für chronische hcv patienten Active DE602005015605D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04450200 2004-10-29
PCT/EP2005/054773 WO2006045677A1 (en) 2004-10-29 2005-09-23 Hcv vaccines for chronic hcv patients

Publications (1)

Publication Number Publication Date
DE602005015605D1 true DE602005015605D1 (de) 2009-09-03

Family

ID=35385494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015605T Active DE602005015605D1 (de) 2004-10-29 2005-09-23 Hcv impfstoff für chronische hcv patienten

Country Status (9)

Country Link
US (2) US20090060875A1 (de)
EP (1) EP1804822B1 (de)
JP (1) JP2008517973A (de)
CN (1) CN101048172A (de)
AU (1) AU2005298742B2 (de)
CA (1) CA2583026A1 (de)
DE (1) DE602005015605D1 (de)
ES (1) ES2327432T3 (de)
WO (1) WO2006045677A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031446A1 (en) * 2003-07-11 2007-02-08 Intercell Ag Hcv vaccines
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
WO2007121491A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
CN102227445B (zh) * 2008-09-30 2014-12-17 东丽株式会社 结合丙型肝炎病毒的包膜蛋白2的抗体以及利用所述抗体鉴定丙型肝炎病毒的基因型的方法
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
US20070031446A1 (en) * 2003-07-11 2007-02-08 Intercell Ag Hcv vaccines
ATE375169T1 (de) * 2000-04-14 2007-10-15 Intercell Ag Modifizierte peptide enthaltende pharmazeutische präparationen
EP1282632A1 (de) * 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
US6337317B1 (en) * 2000-06-27 2002-01-08 The University Of British Columbia Antimicrobial peptides and methods of use thereof
CA2433967A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
US7244438B2 (en) * 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CA2484941A1 (en) * 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients

Also Published As

Publication number Publication date
US20090060875A1 (en) 2009-03-05
CN101048172A (zh) 2007-10-03
WO2006045677A1 (en) 2006-05-04
AU2005298742A1 (en) 2006-05-04
ES2327432T3 (es) 2009-10-29
JP2008517973A (ja) 2008-05-29
CA2583026A1 (en) 2006-05-04
AU2005298742B2 (en) 2010-08-12
EP1804822A1 (de) 2007-07-11
EP1804822B1 (de) 2009-07-22
US20100322972A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DK1747036T3 (da) Inhalatorindretning
DE602004000432D1 (de) Touchscreen
DE502005010058D1 (de) Entschäumerzusammensetzungen
DE602005005920D1 (de) Befestigungsvorrichtung für Rollstuhl
DE602005018315D1 (de) Rollstuhl
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
FR2874166B1 (fr) Agrafe chirurgicale
DE502005010242D1 (de) Entschäumerzusammensetzungen
FI20050836A (fi) Röntgenlaite
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE602005020905D1 (de) Röntgengerät
DE602004010313D1 (de) Orthodontischer indikator
DE602004011962D1 (de) Armstütze für Operateur
FR2872694B1 (fr) Instrument medical
DE112006001343A5 (de) Patientenauflage
DE602005015605D1 (de) Hcv impfstoff für chronische hcv patienten
DE602005006534D1 (de) Piperidinyl-prostaglandin-e-analoga
SE0400530L (sv) Förfarande
DE112005001019A5 (de) Kunststoffschraubverschlusskappe
ITVI20040168A1 (it) Blocchetto indicatore
ATA9982004A (de) Tiefbohrbrunnen
NO20043762D0 (no) Fôr
NO20041954D0 (no) Fôr
NO20042917D0 (no) Osteosyntesemateriale

Legal Events

Date Code Title Description
8364 No opposition during term of opposition